CANSCAN Trial Evaluates Semiautonomous Vascular Mapping With Vexev VxWave Imaging System

November 19, 2025—Vexev and U.S. Renal Care announced the results of the CANSCAN feasibility trial, which provided evidence that Vexev’s VxWave ultrasound imaging system can reliably perform semiautonomous vascular mapping examinations directly within the dialysis clinic.

Vexev is an Australia-based vascular imaging company and U.S. Renal Care is a provider of in-center and home dialysis in the United States. The companies announced completion of enrollment in the trial in July 2025.

Varshi Broumand, MD, Principal Investigator of CANSCAN, presented the results at Kidney Week 2025, the American Society of Nephrology’s annual meeting.

According to the companies, the multicenter feasibility study evaluated the use of semiautonomous ultrasound scanning with the VxWave system. The investigators scanned 115 patients with severe kidney damage or end-stage renal disease (chronic kidney disease [CKD] stage 4 and 5).

As summarized in the Vexev and U.S. Renal Care press release, the study’s primary endpoints demonstrated a 94% scan completion rate, 100% data adequacy rate, and 98% of access options (including arteriovenous graft or arteriovenous fistula) were determined feasible in patients.

The companies further stated that the trial provided insights into the upper limb vascular anatomy of CKD stage 4 and 5 patients and identified subgroups who may be at a disadvantage for vascular access creation. Specifically, patients with diabetes had significantly more calcification in the upper limb arteries and a reduction in forearm distal vascular diameters. Additionally, female patients were found to have statistically fewer available veins and smaller veins overall compared to males.